Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 11 studies | 43% ± 24% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 39% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 73% | 4473.10 | 1934 / 2642 | 46% | 2.04 | 327 / 705 |
kidney | 70% | 143.57 | 62 / 89 | 41% | 1.32 | 371 / 901 |
adipose | 90% | 330.06 | 1078 / 1204 | 0% | 0 | 0 / 0 |
breast | 61% | 157.50 | 282 / 459 | 16% | 0.75 | 184 / 1118 |
adrenal gland | 52% | 78.28 | 134 / 258 | 14% | 0.39 | 32 / 230 |
blood vessel | 50% | 102.63 | 667 / 1335 | 0% | 0 | 0 / 0 |
skin | 31% | 202.93 | 569 / 1809 | 18% | 1.18 | 86 / 472 |
lung | 36% | 56.63 | 206 / 578 | 13% | 0.51 | 151 / 1155 |
thymus | 32% | 44.08 | 207 / 653 | 12% | 0.21 | 74 / 605 |
liver | 33% | 49.55 | 75 / 226 | 10% | 0.44 | 40 / 406 |
uterus | 29% | 44.74 | 49 / 170 | 6% | 0.29 | 28 / 459 |
pancreas | 20% | 34.10 | 66 / 328 | 8% | 0.23 | 15 / 178 |
intestine | 21% | 31.04 | 204 / 966 | 4% | 0.11 | 19 / 527 |
heart | 16% | 33.30 | 137 / 861 | 0% | 0 | 0 / 0 |
esophagus | 0% | 0.60 | 6 / 1445 | 12% | 0.37 | 22 / 183 |
ovary | 7% | 13.64 | 13 / 180 | 3% | 0.12 | 13 / 430 |
stomach | 1% | 0.55 | 2 / 359 | 7% | 0.13 | 19 / 286 |
bladder | 0% | 0 | 0 / 21 | 7% | 0.18 | 36 / 504 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.52 | 2 / 29 |
prostate | 2% | 2.41 | 4 / 245 | 4% | 0.15 | 21 / 502 |
peripheral blood | 3% | 4.29 | 28 / 929 | 0% | 0 | 0 / 0 |
spleen | 2% | 2.23 | 4 / 241 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.75 | 2 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0061590 | Biological process | calcium activated phosphatidylcholine scrambling |
GO_0034220 | Biological process | monoatomic ion transmembrane transport |
GO_0050982 | Biological process | detection of mechanical stimulus |
GO_0016048 | Biological process | detection of temperature stimulus |
GO_0061591 | Biological process | calcium activated galactosylceramide scrambling |
GO_1902476 | Biological process | chloride transmembrane transport |
GO_0051649 | Biological process | establishment of localization in cell |
GO_0005886 | Cellular component | plasma membrane |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0005229 | Molecular function | intracellularly calcium-gated chloride channel activity |
GO_0005254 | Molecular function | chloride channel activity |
GO_0017128 | Molecular function | phospholipid scramblase activity |
Gene name | ANO3 |
Protein name | Anoctamin 3 Anoctamin Anoctamin-3 (Transmembrane protein 16C) |
Synonyms | TMEM16C GENX-3947 C11orf25 |
Description | FUNCTION: Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylcholine and galactosylceramide (By similarity). Seems to act as potassium channel regulator and may inhibit pain signaling; can facilitate KCNT1/Slack channel activity by promoting its full single-channel conductance at very low sodium concentrations and by increasing its sodium sensitivity (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity . . |
Accessions | ENST00000256737.8 [Q9BYT9-1] ENST00000531646.1 Q9BYT9 A0A5F9ZHL6 ENST00000531568.1 [Q9BYT9-2] ENST00000672621.1 E9PQ79 ENST00000525139.5 E9PKW2 |